PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

Yu Wang; Yong-Bo Xiang; Xiao-Wei Chen; Tao Zhang; Jian-Yang Wang; Wen-Yang Liu; Lei Deng; Lu-Hua Wang; Shu-Geng Gao; Nan Bi

doi:10.1186/s40779-025-00679-z

Your Location：

Home >

Browse articles >

PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

RESEARCH | Updated：2026-06-10

- PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
- PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
- Military Medical Research 2026年13卷第5期页码：747-765
- Affiliations：
  
  1.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  2.Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  3.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China
  4.Key Laboratory of Minimally Invasive Therapy Research for Lung Cancer, Chinese Academy of Medical Sciences, Beijing 100021, China
  5.State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Author bio：
  
  * Shu-Geng Gao gaoshugeng@vip.sina.com
  Nan Bi binan_email@163.com
- Funds：
  
  the National Natural Science Foundation of China(82373216;12405407);the CAMS Innovation Fund for Medical Sciences(2024-I2M-ZD-004);the Special Research Fund for Central Universities, Peking Union Medical College(3332023026)
- DOI：10.1186/s40779-025-00679-z
  中图分类号：
- 收稿：2025-01-26，
  
  录用：2025-11-25，
  
  网络首发：2026-01-06，
  
  纸质出版：2026-05
- Accepted：
Scan QR Code
Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, 等. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J]. Military Medical Research, 2026,13(5):747-765.

Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J]. Military Medical Research, 2026, 13(5): 747-765.
Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, 等. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J]. Military Medical Research, 2026,13(5):747-765. DOI： 10.1186/s40779-025-00679-z.

Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J]. Military Medical Research, 2026, 13(5): 747-765. DOI： 10.1186/s40779-025-00679-z.

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Enhancing the clinical relevance of haemorrhage prediction models in trauma

Artificial intelligence and machine learning for hemorrhagic trauma care

Cell-free DNA in sepsis: from molecular insights to clinical management

The "cytokine storm" in infection and sepsis:win the battle but lose the war

A methodological guideline for consciousness assessment via neural electrophysiological activity

PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

DOI：10.1186/s40779-025-00679-z